Skip to main content
Premium Trial:

Request an Annual Quote

Physiome Licenses PathwayPrism Technology to 3rd Millennium

NEW YORK, Aug. 28 – Physiome Sciences has licensed its PathwayPrism modeling technology to 3rd Millennium to help it develop products for Huntington’s disease, the companies said on Tuesday.

The deal will allow Cambridge, Mass.-based 3rd Millennium and its academic partners “to visualize and stimulate pathways” involved in the disease, the companies said in a statement.

“We chose Physiome’s technology after a thorough review because it represents the best method for building, visualizing, and stimulating disease pathways like Huntington’s,” Richard Dweck, president of 3rd Millennium, said in the statement.

Financial terms of the licensing agreement were not disclosed, and representatives from either company were not immediately available for comment.

3rd Millennium, a privately held firm that develops life science-based information systems, will combine its deal with Physiome with its newly developed data integration technology.

This technology, which was paid for in part through a two-year, $1.8 million Advanced Technology Program grant, has been designed to store and integrate many types of biologic data along with their biological content, the companies said. This provides computer models that combine “context of organs, tissues, and cells with gene expression, interaction, and functional data,” they added.

Huntington’s disease, a fatal, autosomal-dominant neurological disease that causes psychosis and dyskinesia, was chosen because of the amount of publicly available data about it, the companies said.

Last week, IBM and Physiome, of Princeton, NJ, entered into a non-exclusive alliance that would combine IBM's supercomputing technology with Physiome’s biological modeling software.  

The deal , which makes IBM Physiome's preferred IT supplier for custom computing, will allow Physiome to “speed up” its ability to simulate models of various cells, tissues and organs, and affect the behavior of certain disease states. 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.